New Tube-Feeding formula aims to steady blood sugar in diabetics

NCT ID NCT05859165

Completed Disease control Sponsor: Société des Produits Nestlé (SPN) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study tested whether a diabetes-specific tube-feeding formula (Nutren Diabetes) can control blood sugar as well as another formula (Fresubin Diabetes) in diabetic patients who have trouble swallowing. 233 adults aged 18-90 took part, receiving tube feeding for up to 12 days. The main goal was to compare average blood sugar levels over 24 hours between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nutren Diabetes (a diabetes-specific tube-feeding formula)
What this could lead to: If it works, this could provide a safe and effective nutritional option for diabetic patients who need tube feeding, helping to keep their blood sugar stable.
What could go wrong: This is a small, completed non-inferiority trial, so results may not apply to all patients. The formula is a dietary supplement, not a drug, so benefits are limited to nutritional support.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS

Contacts and locations

Locations

Peking Union Medical College hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.